OHSU Knight Cancer Institute Research Groups:Members

Home        Faculty        Graduate Program        Postdocs        OHSU Knight Core Facilities       

Programs     Res Group Meetings        Cancer Journal Club        Cell/CANB 616        Gen. Inst/R3 Club     CANB 610    

**under construction**

Primary Faculty

Eric Barklis,PhD

Professor

OHSU faculty page
Research in the Barklis lab focuses on the assembly and replication of viruses, such as retroviruses, flaviviruses, and hantaviruses, using molecular genetic, biochemical, and biophysical techniques. Molecular genetic and biochemical are employed to investigate viral protein interactions, RNA recognition and encapsidation, and cellular factors involved in virus replication and assembly. To analyze virus particles, proteins, and macromolecular complexes, a variety of biophysical methods are utilized, including sedimentation, crosslinking, fluorescence microscopy, fluorescence anisotropy, transmission electron microscopy (EM), and atomic force microscopy (AFM). One set of recent investigations concentrates on the identification and analysis of small molecule inhibitors of virus replication. A second avenue of inquiry concerns the mechanisms that govern how HIV structural proteins assemble conical, cylindrical and spherical cores. Our third major area of research focuses on protein-protein and protein-lipid interactions of retrovirus membrane-binding proteins. Ultimately, we believe our studies will lead to the development of new antivirals, and a better understanding of the basic principles controlling macromolecular assembly.

Michael Deininger, MD,PhD

Associate Professor

OHSU Faculty Page
Joining OHSU in 2002, Dr. Deininger`s clinical interests concentrate on bone marrow transplantation and leukemia. His research focuses on the molecular basis of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Our work in the Hematology and Medical Oncology Division is dedicated to the study and treatment of cancer and disorders of the blood in adults. Research in the diagnosis and treatment of various anemias, lymphomas, leukemias and pre-leukemia, cancer of the lung, prostate, breast, colon, head and neck, testicular cancer, thrombosis and coagulation disorders, aging, supportive care and bone marrow failure are integral elements of our clinical practice. Our laboratory research is conducted in the interest of coagulation, hematopoiesis, tumor immunology, transplantation immunology, DNA repair, leukemogenesis, HIV biology, cell cycle control, retroviral mediated gene transfer, cancer chemotherapeutics, and gene therapy

Brian Druker, MD

Professor

OHSU Faculty Page
Dr. Druker's current research projects are aimed at learning why each year some 4% of newly diagnosed patients with CML develop resistance to Gleevec and why most patients on the drug have minute levels of cancer that linger even after treatment ends. Resistance to Gleevec most commonly results from mutations in the BCR-ABL kinase that reactivates its signaling mechanism. He recently identified a class of compounds that can inhibit most of these mutants, and similar compounds are now in clinical trials. A more pressing problem, Druker believes, are the traces of leukemia that remain in patients' bodies, a phenomenon called molecular persistence. He is working in the laboratory to purify leukemia cells from patients to determine why these cells aren't being killed so that a strategy can be developed to eradicate the cancer.

William Fleming,PhD

Professor
OHSU faculty page
Over the past several years, my laboratory has been interested in functional relationship between hematopoiesis and blood vessel formation. Recently, we have found that adult vascular endothelial cells are an important component of the hematopoietic microenvironment. Specifically, endothelial cells can produce signals that protect hematopoietic stem cells (HSCs) from radiation induced cell death. Classical studies in embryology demonstrated the existence of the hemangioblast, a stem cell that can give rise to both hematopoiesis and blood vessels. To address the question of whether bone marrow derived cells with hemangioblast activity exist in the adult, the vascular compartment of bone marrow transplanted mice and humans was carefully evaluated for the presence of donor derived cells. A similar frequency of bone marrow derived endothelial cells was detected in both mouse and human transplant recipients. A single HSC can give rise to both hematopoietic and endothelial cells in vivo providing direct evidence for the existence of an adult hemangioblast. Additional studies demonstrate that endothelial cells can arise from hematopoietic progenitors cells committed to the myelomonocytic cell lineages. These functional interactions between HSCs and blood vessels represent a new area of investigation that has important implications for our understanding of both normal and malignant hematopoiesis.

Markus Grompe, MD

Professor

OHSU Faculty Page
Single gene disorders, although individually rare, cumulatively represent a significant medical burden, particularly in the pediatric age group. Current treatment options are very limited and outcomes remain poor in many cases. Gene transfer and cell therapy (including stem cell transplantation) are hopeful strategies for future therapies. It is our long-term goal to develop these into clinically useful procedures. Our particular focus is metabolic liver diseases and the DNA repair disease Fanconi Anemia.

Michael Heinrich, MD

Professor

OHSU Faculty Page
Michael Heinrich M.D. earned his medical degree in 1984 from Johns Hopkins School of Medicine in Baltimore and completed both his residency training and Hematology and Medical Oncology fellowship at OHSU. His primary research interest is in the development of novel tyrosine kinase inhibitors for treatment of human cancers. Dr. Heinrich's research includes both pre-clinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. Dr. Heinrich has extensive national and international collaborations for his research into the molecular biology of sarcomas and hematologic malignacies.

Ann Hill, PhD

Professor

OHSU Faculty Page
My lab is interested in the immunobiology of cytomegalovirus (CMV). CMV is a beta herpesvirus; like most herpes viruses it establishes lifelong asymptomatic infection. The immune system, however, becomes uniquely obsessed with CMV, devoting an increasing proportion of the T cell response to CMV over an individual’s lifetime. In old age this response can become truly enormous. Our main focus is understanding how this lifelong “détente” between virus and host is maintained. What does the virus do to prevent the immune system from eradicating it? How does the immune system keep the virus under control, and why is it so “obsessed”? How active is the guerilla war that host and virus wage? What are the implications for human health? We work mostly in the mouse model, and have performed a detailed characterization of the CD8 T cell response to murine (M)CMV in C57BL/6 mice, and have investigated the mechanism and impact of MHCI immune evasion in this model.

Maureen Hoatlin, PhD

Associate Professor

OHSU Faculty Page
We are interested in understanding how cells maintain genomic stability. One of the mechanisms that regulates this critical process is defective in Fanconi anemia (FA), a genetic model for human host susceptibility to cancer. FA is a rare but devastating multi-gene disease thought to have an underlying defect in DNA interstrand crosslink repair.

Our Labpioneered the use of cell-free assays for FA proteins in extracts from Xenopus eggs. These extracts allow analysis of FA protein function and post-translational modifications in a context that is permissive for naturally regulated DNA synthesis. The recruitment of Fanconi proteins with chromatin in S-phase is providing us with a biochemical platform for elucidating the molecular function of the Fanconi proteins during the DNA damage response.

Molly Kulesz-Martin, PhD

Professor

OHSU Faculty Page
Tripartate Motif Protein 32 (Trim32) is a novel E-3 ligase and scaffold protein with specificity for substrate proteins that regulate apoptosis, potentially explaining its role in disorders of cellular failure to die, such as psoriasis and neoplasia, when activated and in muscular dystrophy type 2H when inactivated. We are studying two aspects of Trim32 function: its role in human keratinocyte survival disorders and its regulation of activity of PIASgamma/y and other substrates by targeting them for proteolysis. We have identified substrates of Trim32, in particular the SUMOligase Piasy, by yeast two hybrid and interaction and functional domains by targeted mutagenesis approaches. We are using targeted knock down or expression by lentiviral or adenoviral systems in cell culture and in mice to dissect the role of Trim32/its substrates in initiation and malignant conversion.

Map kinase phosphatases (MKP) have dual roles in activation or inhibition of cellular differentiation or apoptosis through ERK1/2, jun kinase (JNK) or p38 kinase. We discovered downregulation of an MKP associated with rapid progression to malignancy and metastasis in a microarray/metagene analysis of skin carcinogenesis. We are using targeted/inducible gene expression and knock down strategies in cell culture and in mice to study the MKP role in regulation of MAPK functions in balancing cell proliferation, differentiation and apoptosis and cellular transformation and malignant progression.

The p53 family proteins as critical regulators of cellular response to DNA damage and stress signals and provide the context for the roles of putative initiators such as Trim32 and MKP4 in malignant conversion. We have detected p53 and p63 loss of function and dramatic downregulation of p73 during multistage carcinogenesis. As in at least half of human tumors, these losses occur without p53 family gene mutations. Using novel DNA binding assays to determine isoform specificity of action of this complex family, we are tracing the differential interactions of endogenous p53 family proteins with regulatory proteins partners and with DNA. Understanding p53 family protein ability to orchestrate the cell cycle, apoptosis and differentiation response to ionizing and ultraviolet radiation and other stresses may open new approaches to treat human disease.

Mike Liskay, PhD

Professor

OHSU Faculty Page
We use yeast and mice to study DNA mismatch repair (MMR),which corrects mismatches and senses DNA damage. MMR gene mutations increase spontaneous mutation and predispose to hereditary and sporadic cancer. Using gene targeting strategies, we derive and study knockout mice for four MutL homologs, Mlh1, Pms1 or Pms2, and Mlh3. We have observed increased mutation and cancer risk in these animals although the severity varies between the different knockouts. In a related project, we have developed an assay using the site-specific recombinase Cre to stochastically inactivate tumor suppressor genes or activate oncogenes in the mouse. The system also uses a color marker (b-galactosidase) which is activated by the recombinase thus marking those celllineages experiencing inactivation (or activation) of the "loxp"-tagged tumor suppressors/oncogenes. One question being addressed is "What is the minimum number of gene alterations necessary to promote intestinal tumor formation and progression in the mouse?" Our studies in yeast are centered on a better understanding of mechanism and the gene products involved in DNA mismatch repair.

Grompe Lab MMG

Mike Heinrich-Chris Corless Labs

Hoatlin Lab Biochemistry and Molecular Biology (BMB)

Kurre Lab Pediatrics

Liskay Lab Molecular and Medical Genetics (MMG)

Lloyd Lab Center for Research on Occupational and Environmental Toxicology (CROET)

Lopez Lab Hem Onc

McCullough Lab CROET & MMG

Sears Lab

Thayer Lab BMB

Turker Lab CROET

Wong Lab

Affiliate Labs

Singer Lab Portland State University, Biology Dept.

• Starting your Lab wiki on OWW